Panel Advises 5,000-Patient Postmarket Study For Medtronic’s DES
This article was originally published in The Gray Sheet
Executive Summary
Medtronic should conduct a large postmarket study to monitor late stent thrombosis and help define the appropriate antiplatelet drug regimen for drug-eluting stent patients, FDA's Circulatory System Devices Panel recommended at its Oct. 10 meeting in Gaithersburg, Md
You may also be interested in...
FDA Advisory Panel Cautiously Endorses Abbott Xience V Drug-Eluting Stent
FDA's Circulatory System Devices panel overwhelmingly endorsed PMA approval of Abbott's Xience V everolimus-eluting, despite reservations about its long-term safety
FDA Advisory Panel Cautiously Endorses Abbott Xience V Drug-Eluting Stent
FDA's Circulatory System Devices panel overwhelmingly endorsed PMA approval of Abbott's Xience V everolimus-eluting, despite reservations about its long-term safety
Will FDA’s New Requirements For Drug-Eluting Stents Impact Innovation?
Shifting regulatory requirements are compelling medical device companies, both big and small, to be more prudent with their R&D dollars